TORONTO, June 26, 2019 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) announces that it has informed Health Canada that it will be withdrawing its New Drug Submissions for two cardiovascular products, subsequent to the Notice of Deficiency received from Health Canada earlier this year in respect of these […]